Interim Report 2026
Filed with HKEX · Stock code 2105 · · 59 pages · English
Earlier from Laekna
- New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
- ADA 2025 | Laekna Presented Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123
- Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
- Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
- Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
Later from Laekna
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement updates on the 24-week monotherapy study of LAE102 showed promising weight losses favorable changes in body composition and well tolerated safety profile
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Laekna into a list and get an email when it puts out news.
Follow Laekna